[1] DIDIER D K, SCHIFFENBAUER J, WOULFE S L, et al. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box[J]. Proc Natl Acad Sci USA, 1988, 85(19): 7322-7326.
[2] LYABIN D N, ELISEEVA I A, OVCHINNIKOV L P, et al. YB-1 protein: functions and regulation[J]. Wiley Interdiscip Rev RNA,
2014, 5(1): 95-110.
[3] MACIEJCZYK A, SZELACHOWSKA J, EKIERT M, et al. Elevated nuclear YB1 expression is associated with poor survival of
patients with early breast cancer[J]. Anticancer Res, 2012, 32(8): 3177-3184.
[4] MAKINO Y, OHGA T, TOH S, et al. Structural and functional analysis of the human Y-box binding protein(YB-1) gene
promoter[J]. Nucleic Acids Res, 1996, 24(10): 1873-1878.
[5] MATSUMOTO K, BAY B H. Significance of the Y-box proteins in human cancers[J]. J Mol Genet Med, 2005, 1(1): 11-17.
[6] LASHAM A, MOLONEY S, HALE T, et al. The Y-box-binding protein, YB1 is a potential negative regulator of the p53 tumor
suppressor[J]. J Biol Chem, 2003, 278(37): 35516-35523.
[7] DAVIES A H, REIPAS K M, PAMBID M R, et al. YB-1 Transforms human mammary epithelial cells through chromatin
remodeling leading to the development of basal-like breast cancer[J]. Stem Cells, 2014, 32(6): 1437-1450.
[8] JURCHOTT K, BERGMANN S, STEIN U, et al. YB -1 as a cell cycle regulated transcription factor facilitating cyclin A and cyclin B1 gene expression[J]. Biol Chem, 2003, 30(278): 27988-27996.
[9] MASANORI H, YOJIRO K, TATSUYA O. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers[J]. Genes to Cell, 2014, 19(6): 504-516.
[10] ELISEEVA I A, KIM E R, GURYANOV S G, et al. Y-box binding protein 1 (YB-1) and its functions[J]. Biochemistry, 2011, 76(13): 1402-1433.
[11] LASHAM A, SAMUEL W, CAO H, et al. YB-1, the E2F pathway and regulation of tumor cell growth[J]. J Natl Cancer Inst, 2012,
104(2): 133-146.
[12] ASTANEHE A, FINKBEINER M R, HOJABRPOUR P, et al. The transcriptional induction of PLK3CA in tumor cells is
dependent on the oncoprot ein Y-box binding protein-1[J]. Oncogene, 2009, 28(25): 2406-2418.
[13] MOISEEVA, STROMSKAYA, RYBALKINA, et al. Effects of extracelluar YB-1 protein on cultured cells of human breast
cancer[J]. Biochemistry, 2013, 7(8): 21-28.
[14] EVDOKIMOVA V, TOGNON C, NG T, et al. Translational activation of snail1 and otherdevelopmentally regulated transcription factors by YB-1 promotes an epithelial mesenchymal transition[J]. Cancer Cell, 2009, 15(1): 402-415.
[15] FRYE B C, HALFTER S, DJUDJAJ S, et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen[J]. EMBO Rep, 2009, 10(7): 783-789. [16] HA Bin, EUN B L, CUI Jun, et al. YB-1 overexpression promotes a TGF-b1- induced epithelial emesenchymal transition via Akt activation[J]. Biochemical and Biophysical Reaearch Communications, 2015, 458(2): 347-351.
[17] ZHANG Hai, CHENG Shanyu, ZHANG Min, et al. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through
upregulation of YB-1 protein expression[J]. Int J Oncol, 2014, 44(3): 769-780.
[18] GUO Tiantian, YU Yingnan, YIP G W. Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro[J]. Anat
Rec(Hoboken), 2013, 296(6): 891-898.
[19] LEE C, DHILLON J, WANG M Y, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the
mTOR/STAT3 pathway and suppresses tumor growth in mice[J]. Cancer Res, 2008, 68(21): 8661-8666.
[20] HANZAWA K, MOMOSE S, HIGASHI M, et al. Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact
on prognosis in the rituximab era[J]. Leukemia Lymphoma, 2010, 51(11): 2054-2062.
[21] GIMENEZ B P, FEDORUK M N, WHITMORE T G, et al. YB-1 is glycoprotein activity[J]. Prostate, 2004, 59( 3): 337-349.
[22] BARGOU R C, JURCHOTT K, WAGENER C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression[J]. Nat Med, 1997, 3(4): 447-450.
[23] KOLL F J, MANTWILL K, SCHMID S C, et al. Treatment of bladder cancer with YB-1 dependent oncolytic adenovirus:
Preliminary in vitro studies[J]. Eur Urol Suppl, 2015, 14(2): 1-32. [24] KOSTOVA Y, MANTWILL K, HOLM P S, et al. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a
combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment[J]. Cancer Gene
Therapy, 2015, 22(1): 30-43.
|